Skip to main content
SpringerLink
Log in

La stimulation multifolliculaire

  • Chapter
Pratique de la stimulation ovulatoire par les gonadotrophines

  • 293 Accesses

Résumé

La stimulation ovarienne nécessaire et exclusive à la pratique de la fécondation in vitro (FIV) présente des différences importantes par rapport à la stimulation classique mono-ou paucifolliculaire.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Steptoe PC, Edwards RG (1978) Birth after the reimplantation of a human embryo. Lancet 12: 366

    Article  Google Scholar 

  2. Emperaire JC, Ruffie A, Audebert AJM (1986) Fécondation in vitro: à la recherche du meilleur protocole de stimulation. Contracept Fertil Sexual 14: 689–95

    Google Scholar 

  3. Loh S, Maheshwari A (2011) Anti-Mullerian hormone — is it a crystal ball for predicting ovarian ageing? Hum Reprod 36: 2925–32

    Article  Google Scholar 

  4. Pinto E, Pinelo S, Osorio M et al. (2012) Outcomes from ovarian hyperstimulation following the sole administration of gonadotrophin-releasing hormone agonist in the context of in vitro fertilization: report of two cases and review of the literature. Gynecol Endocrinol 28: 545–8

    Article  CAS  PubMed  Google Scholar 

  5. Propovic-Todorovic B, Loft A et al. (2003) A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a “standard” dose of 150 UI/day in “standard “patients undergoing IVF/ICSI treatment. Hum Reprod 18: 2275–82

    Article  Google Scholar 

  6. Howles CM, Saunders H, Alam V, Engrand P (2006) Predictive factors and a corresponding treatment algorithm for controlled ovarian hyperstimulation in patients treated with recombinant human follicle stimulating hormone (follitropin alpha) during assisted reproduction technology (ART) procedures. An analysis of 1378 patients. Curr Med Res Opin 22: 907–18

    Article  CAS  PubMed  Google Scholar 

  7. Loumaye E, Engrand P, Howles CM, O’Dean L (1997) Assessment of the role of serum luteinizing hormone and œstradiol response to follicle stimulating hormone on in vitro fertilization treatment outcome. Fertil Seril 67: 889–99

    Article  CAS  Google Scholar 

  8. Guivarc’h-Leveque A, Arvis P, Broux PL et al. (2005) Confort et efficacité des cycles FIV/ICSI « Antagonistes administrés à jour fixe, prétraités et programmés par E2 ». Poster FFER

    Google Scholar 

  9. Montagut J, Nogueira D, Prat L et al. (2007) GnRH antagonist used from the first day of menses in PCO for IVF/ICSI treatment: comparison of outcomes between cetrorelix and ganirelix. Hum Reprod 22:304

    Google Scholar 

  10. Emperaire JC (2004) Introduction of the antagonist: on a determined day or depending on follicular growth? Gynecol Obstet Fertil 33: 3S39–41

    CAS  Google Scholar 

  11. Emperaire JC, Parneix I, Perraguin-Jayot S (2003) Revisiting the clomiphenegonadotropin protocol in IVF with the use of a GnRH antagonist. Gynecol Obstet Fertil 31: 927–31

    Article  PubMed  Google Scholar 

  12. Frydman R (2004) GnRH antagonists in natural cycle. J Gynecol Obstet Biol Reprod 33:46–9

    Google Scholar 

  13. Humaidan P, Ejdrup Bredkjaer H, Bungum L et al. (2005) GnRH agonist (Buserelin) or HCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 20: 1213–20

    Article  CAS  PubMed  Google Scholar 

  14. Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, Yding Andersen C (2010) 1500 UI human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone is used for ovulation induction: a prospective, randomized, controlled study. Fertil Seril 93:847–54

    Article  CAS  Google Scholar 

  15. Tarlatzis BC, Fauser BC, Kolibianakis EM et al. (2006) On behalf of the Brussels GnRH Antagonist Consensus workshop Group. Hum Reprod Update 13: 333–40

    Article  Google Scholar 

  16. Emperaire JC, Parneix I (2007) Les antagonistes en FIV: Quelle place ? Quel monitorage ? Éditions Frison-Roche, Paris, 2007

    Google Scholar 

  17. Olivennes F, Belaisch Allart J, Emperaire JC, et al. (2000) Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 73: 314–20

    Article  CAS  PubMed  Google Scholar 

  18. Emperaire JC (2006) Minimal ovarian stimulation: certainly less dangerous and probably as efficient. Gynecol Obstet Fertil 11: 540–2

    Google Scholar 

  19. Fauser BCJM, Nargund G, Nyboe Andersen A (2010) Mild ovarian stimulation for IVF: 10 years later. Hum Reprod 25: 2678–84

    Article  PubMed  Google Scholar 

  20. Ferraretti AP, La Marca A, Fauser CJM (2011) On behalf of the ESHRE working group on Poor Ovarian Response Definition. Hum Reprod 26: 1616–24

    Article  CAS  PubMed  Google Scholar 

  21. Oudendijk JF, Yarde F, Eijkemans MJC (2012) The poor responder in IVF: is the prognosis always poor? A systematic review. Hum Reprod Update 18: 1–11

    Article  CAS  PubMed  Google Scholar 

  22. De Ziegler D, Streuli I, Meldrum DR, Chapron C (2011) The value of growth hormone supplements in ART for poor ovarian responders. Fertil Steril 96: 1069–76

    Article  Google Scholar 

  23. Wiser A, Gonen O, Ghetler Y et al. (2010) Addition of dehyroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: A randomized prospective study. Hum Reprod 25: 2496–500

    Article  CAS  PubMed  Google Scholar 

  24. Lee VC, Chan CC, Ng Eh, Yeung WS Ho PC (2011) Sequential use of Letrozole and gonadotrophin in women with poor ovarian response: a randomized control trial. Reprod Biomed Online 23: 380–8

    Article  CAS  PubMed  Google Scholar 

  25. Scott RT, Navot D (1994) Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization. Fertil Steril 61: 5:880–5

    Google Scholar 

  26. Park WI, Kim SS, Chung HR, et al. (2004) Early and late hormonal responses to the microdose gonadotropin-releasing hormone agonist in normal menstruating women. Fertil Steril 81(4)1067–72

    Article  CAS  PubMed  Google Scholar 

  27. Ovieto R, Kruchkovich J, Rabinson J (2007) Ultrashort gonadotropin-releasing hormone agonist combined with flexible multidose gonadotropin-releasing hormone antagonist for poor responders in in vitro fertilization/embryo transfer programs. Fertil Steril 90: 228–30

    Article  Google Scholar 

  28. Reiftmann L, Dechaud H, Loup V, et al. (2007) Le cycle naturel en Fécondation In Vitro chez les mauvaises répondeuses. Gynec Obstet Fertil 35: 352–8

    Article  Google Scholar 

  29. De PLacido G, Alviggi C, Mollo A, et al. (2004) Effects of recombinant LH (rLH) supplementation during controlled ovarian hyperstimulation (COH) in normogonadotrophic women with an initial inadequate response to recombinant FSH (rFSH) after pituitary downregulation. Clin Endocrinol 60:637–43

    Article  Google Scholar 

  30. Berkkanoglu M, Ozgur K (2010) What is the maximal gonadotropin dosage used in microdose flare-up cycles in poor responders? Fertil Steril 94(2)662–5

    Article  CAS  PubMed  Google Scholar 

  31. Vollenhoven B, Osianlis T, Catt J (2008) Is there an ideal stimulation regimen for IVF for poor responders and doest it change with age? Assist Reprod Genet 25:523–9

    Article  Google Scholar 

  32. Biasoni V, Patriarca A, Dalmasso P et al. (2011) Ovarian sensitivity index is strongly correlated to circulating AMH and may be used to predict ovarian response to exogenous gonadotropins in IVF. Reprod Biol Endocrinol 9: 112–6

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Gynro VK, Grynberg M, Scheffer JB et al (2011) Serum anti Müllerian hormone levels are negatively related to Follicular Output RaTe (FORT) in normo-cycling women undergoing controlled ovarian hyperstimulation. Hum Reprod 26: 671–7

    Article  Google Scholar 

  34. Kummer NE, Feinn RS, Griffin DW et al (2013) Predicting successful induction of oocyte maturation after gonadotropin releasing hormone agonist (GnRHa) trigger. Hum Reprod 145: 56–61

    Google Scholar 

  35. Huang R, Fang C, Xu s et al (2012) Premature progesterone rise negatively correlated with live birth rate in IVF cycles with GnRH agonist: an analysis of 2,566 cycles. Fertil Steril 98: 664–70

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre FIV, Clinique Jean Villar, 33520, Bruges, Belgium

    Jean-Claude Emperaire

Authors
  1. Jean-Claude Emperaire
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag France

About this chapter

Cite this chapter

Emperaire, JC. (2013). La stimulation multifolliculaire. In: Pratique de la stimulation ovulatoire par les gonadotrophines. Springer, Paris. https://doi.org/10.1007/978-2-8178-0398-2_12

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0398-2_12

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0397-5

  • Online ISBN: 978-2-8178-0398-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation